Exploring RIFSOL: Pioneering DeSci for Longevity

CoinEx
3 min readNov 19, 2024

--

Introduction

The pump.fun ecosystem is going strong, is the fastest growing category in all of the crypto ecosystem, and it’s doing better even than Bitcoin. The problem is that it’s very hard to identify the tokens that actually outperform the rest, and as with every market, the returns are concentrated in just a few assets.

There is currently a contender from the pump.fun Solana ecosystem is among the outperformers in the crypto market, and this token by the name RIFSOL has risen over 160% in the last 24 hours alone as of November 18, 2024.

What is the RIFSOL token about, and why is it outperforming the crypto market? Continue reading to find out.

What Is Rifampicin?

The RIFSOL token, identified as Rifampicin (ticker: RIF), is a Gamified longevity research platform. Users can speculate on life-extending compounds, stream live experiment data in real-time, and submit their own longevity formulas for testing on model organisms.

Rifampicin is typically known as an antibiotic; however, it has recently gained attention because of its surprising anti-aging properties.

Rifampicin has been proven in small organisms such as C. elegans (a model organism commonly used in aging research) to activate the cell’s innate defense systems against stress and damage.

Consider it a cellular coach, urging cells to be healthy and resilient by defending against harmful oxidative stress and ensuring the integrity of proteins within the cell. These protective properties allow the worms to have longer, healthier lives.

While it is still in its early days, and we don’t know if Rifampicin can do the same in humans, its capacity to enhance cellular health makes it an attractive area of study in the search for anti-aging medicines.

Background and History of Rifampicin

RIFSOL is a meme coin on the Solana pump.fun chain. It is among the tokens under DeSci (Decentralized Science) that was launched in the pump.science platform has been gaining significant momentum recently, even outperforming many other altcoins.

Rifampicin (RIFSOL), in particular from the pump.science, has been surging rapidly in the past few days in the crypto market, even rising over 160% in just a day as of November 18, 2024, thereby grabbing everyone’s attention in the crypto market.

The pump.science platform was launched to show that science is more fun to buy tokens than memes. Round 1 of the pump.science platform focuses on how crypto can help humans live forever.

The RIFSOL token has a total circulating supply of 1 billion tokens.

The Price Change of RIFSOL Token on CoinEx

The RIFSOL token was listed in CoinEx on November 17, 2024. Tradings, deposits, withdrawals and swapping were made available immediately.

The token rose over 160% after being listed on CoinEx, as can be seen in the charts above, and its market capitalization has risen over $200 million as of November 18, 2024.

The RIFSOL token is among the tokens on the DeSci platform, and it has received funding from the Solana Foundation because of its plan to push longevity research forward.

The whole idea of using crypto as a means to help humans life forever is an idea that will have a significant impact on the price of the RIFSOL token, as can be seen already from its performance in the last few days as of November 18, 2024.

Overview

*This article does not constitute investment advice.

About CoinEx

CoinEx was founded in 2017, upholds the “user-first” principle and aims to explore new models in the industry and promote the circulation, application and development of blockchain technology. Supporting 18 language markets, covers over 200 countries and regions, provides more than 1,200 cryptocurrencies trading, and reaches over 1,700 trading markets, serving more than 10 million registered users. As a world-leading exchange, CoinEx has already been established as a comprehensive ecosystem and provides a wide range of service choices, including CoinEx, CoinEx Wallet, CoinEx Smart Chain, CoinEx Explorer and CoinEx Charity.

--

--

No responses yet